Development of integrated patient-specific models of the mitral valve and left ventricle: time dependent effects of ischemic mitral valve regurgitation

Author(s):  
Michael S. Sacks
2021 ◽  
Vol 15 (1) ◽  
pp. 1868-1884
Author(s):  
J. Franz ◽  
K. Czechowicz ◽  
I. Waechter-Stehle ◽  
F. Hellmeier ◽  
F. Razafindrazaka ◽  
...  

2016 ◽  
Vol 66 (2) ◽  
pp. 271-278
Author(s):  
Orhan Pinar ◽  
Aziz Arda Sancak ◽  
Yücel Meral ◽  
Duygu Dalğin

Abstract Mitral valve (MV) disease is the most important valvular condition affecting athletic performance in horses. Twenty and 22 years old Thoroughbred Stallions used for breeding had suffered from increased respiratory and heart rate, poor performance and incomplete ejaculate release during covering, since three months ago. Cardiac examination projected irregular cardiac rhythm after a halt and an early-mid-systolic murmur. Mitral regurgitation (MR) and valvular changes were visible on echocardiography. Also volume overload of the Left Atrium (LA) and Left Ventricle (LV) were observed. Color Flow Doppler echocardiography confirmed moderate mitral valve regurgitation. A band-like fibrous and nodular degeneration of the left coronary leaflet was present. There was minimal secondary left ventricular remodeling of the apex of the left ventricle due to chronic volume overload. The therapeutic attempts included Quinapril and Furosemide. In these cases, normally no structural effect could be achieved, but clinical improvement and successful covering sessions were obtained, and when the therapy was terminated, clinical problems reappeared. In conclusion, in horses with MR, early diagnosis and appropriate therapy with Quinapril promises a reasonable performance.


2021 ◽  
Author(s):  
Robert J Henning

Mitral valve regurgitation (MR) is due primarily to either primary degeneration of the mitral valve with Barlow's or fibroelastic disease or is secondary to ischemic or nonischemic cardiomyopathies. Echocardiography is essential to assess MR etiology and severity, the remodeling of cardiac chambers and to characterize longitudinal chamber changes to determine optimal therapies. Surgery is recommended for severe primary MR if persistent symptoms are present or if left ventricle dysfunction is present with an EF <60% or a left ventricle end-systolic diameter ≥40 mm. For secondary MR, therapy of heart failure with vasodilators and diuretics improves forward cardiac output. Coronary artery bypass grafts (CABG) or percutaneous coronary intervention (PCI) should be considered for severe MR due to ischemia. This review summarizes the pathophysiology, the characteristics, the management and the different interventions for high risk patients with chronic primary and secondary MR.


2021 ◽  
Vol 45 (3) ◽  
pp. 197-206
Author(s):  
Giovanni Alfonso Chiariello ◽  
Saimir Kuci ◽  
Guglielmo Saitto ◽  
Massimo Massetti ◽  
Ottavio Alfieri ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document